Last checked at 18 Nov 2013 10:25
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Scancell Holdings Share News (SCLP)
SCLP Share
Price
SCLP Share
News
SCLP Share
Chat3
SCLP Share
Trades
SCLP
Live RNS1
SCLP Share
Charts
SCLP Level 2
Console
SCLP Live
Share Price
SCLP Broker
Ratings
SCLP Directors
Deals
SCLP Financial
Diary
SCLP
Fundamentals
SCLP Short
Positions
SCLP
Media
Scancell Holdings Information
Share Price Information for Scancell Holdings (SCLP)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
10.20
Bid:
0.00
Ask:
0.00
Change:
0.00 (0.00%)
Spread:
1.00 (10.309%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
10.20
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Scancell Holdings updates on clinical trial of melanoma vaccine
Tue, 29th Jan 2013 09:05
Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma. The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection.The trial is being conducted in five UK centres in patients with Stage III/IV disease to assess the safety of the treatment and the immune response. Patients are being treated with a 4.0mg dose of SCIB1, five times over six months. Last month Scandell released findings from the first phase of the study which showed SCIB1 produced an immune response that may benefit patients with malignant melanoma. At the same the group also announced approval from regulators to treat an extra group of patients with a higher 8.0mg dose of the vaccine."As expected, the recruitment of patients in the second part of the trial proceeded faster than recruitment for the first part of the trial, as we were not constrained by the cohort study design requiring sequential dose escalation, and there were more patients available with earlier stage disease," said Lindy Durrant, Joint Chief Executive Officer (CEO) of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University."The recruitment and dosing of the final patient in part two gives us confidence that this phase of the study will be completed by the end of 2013, consistent with previous expectations."Shares were down 0.59% to 42.25p at 9:19 Tuesday. RD
More News
22 Oct 2013 16:26
Prezzo exec slices off 200,000 shares
Kuldip Sehmi, an Executive Director at Italian restaurant chain Prezzo, on Monday traded in 200,000 shares, reducing his stake to 682,244 shares, equal to 0.29 per cent of the issued share capital. Sehmi, who is responsible for the day to day running of approximately half the Prezzo estate, sold t
Read more22 Oct 2013 09:48
1 Oct 2013 10:02
Scancell reports progress across a number of trials
Scancell, which develops novel immunotherapies for the treatment of cancer, on Tuesday revealed that four out of the six evaluable patients treated with either the 2mg or 4mg dose of its SCIB1 drug still remain alive. It said the mean survival time in this group of five Stage IV and one Stage IIIb
Read more3 Sep 2013 14:13
Scancell secures Australian patent
Scancell said it had received a patent for its DNA ImmunoBody treatment in Australia. Australia is the first jurisdiction to approve the DNA patent. Scancell said it was an important step to comprehensively protecting the technology. Scancell specialises in treatments to encourage the immune sys
Read more23 Jul 2013 16:21
SABMilller Chairman sells over 11m pounds in shares
Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so
Read more6 Feb 2013 11:06
Scancell shares healthy following patent approval award in Japan
Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan. The same patent has already been approved in the US, Europe and Australia. Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This
Read more31 Jan 2013 15:04
Sector movers: Pharmaceuticals under the weather as AstraZeneca takes a hit
The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices. The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at consta
Read more31 Jan 2013 14:33
Six month operating loss increases slightly at Scancell
AIM-listed medical company Scancell has published its unaudited interim results for the six month period to October 31st, showing an overall operating loss of 989,981 pounds. This compared to a loss of £941,674 in the corresponding period in 2011. The cash at bank on October 31st was £2.6m compar
Read more